Patents by Inventor Mark T. Keating
Mark T. Keating has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020100071Abstract: Transgenic mice are genetically engineered for a deficiency in endoglin production. These mice may have a homozygous or hemizygous disruption of the endogenous endoglin gene. Homozygous mice exhibit a lack of endoglin production. The failure to produce endoglin results in arrested development of the vascular system of the mouse and no survival beyond E11.5. These mice and cells derived therefrom provide useful reagents for understanding the development and pathology of the mammalian vascular system.Type: ApplicationFiled: February 4, 2002Publication date: July 25, 2002Inventors: Dean Y. Li, Mark T. Keating
-
Patent number: 6420124Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.Type: GrantFiled: June 19, 2000Date of Patent: July 16, 2002Assignees: University of Utah Research Foundation, Genzyme CorporationInventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
-
Publication number: 20020061524Abstract: Long QT Syndrome (LQTS) is a cardiovascular disorder characterized by prolongation of the QT interval on electrocardiogram and presence of syncope, seizures and sudden death. Five genes have been implicated in Romano-Ward syndrome, the autosomal dominant form of LQTS. These genes are KVLQT1, HERG, SCN5A, KCNE1 and KCNE2. Mutations in KVLQt1 and KCNE1 also cause the Jervell and Lange-Nielsen syndrome, a form of LQTS associated with deafness, a phenotypic abnormality inherited in an autosomal recessive fashion. Mutational analyses were used to screen 262 unrelated individuals with LQTS for mutations in the five defined genes. A total of 134 mutations were observed of which eighty were novel.Type: ApplicationFiled: April 24, 2001Publication date: May 23, 2002Applicant: University of Utah Research FoundationInventors: Igor Splawski, Mark T. Keating
-
Patent number: 6372958Abstract: Transgenic mice are genetically engineered for a deficiency in endoglin production. These mice may have a homozygous or hemizygous disruption of the endogenous endoglin gene. Homozygous mice exhibit a lack of endoglin production. The failure to produce endoglin results in arrested development of the vascular system of the mouse and no survival beyond E11.5. These mice and cells derived therefrom provide useful reagents for understanding the development and pathology of the mammalian vascular system.Type: GrantFiled: May 25, 2000Date of Patent: April 16, 2002Assignee: The University of Utah Research FoundationInventors: Dean Y. Li, Mark T. Keating
-
Patent number: 6342357Abstract: Long QT Syndrome (LQTS) is a cardiovascular disorder characterized by prolongation of the QT interval on electrocardiogram and presence of syncope, seizures and sudden death. Five genes have been implicated in Romano-Ward syndrome, the autosomal dominant form of LQTS. These genes are KVLQT1, HERG, SCN5A, KCNE1 and KCNE2. Mutations in KVLQT1 and KCNE1 also cause the Jervell and Lange-Nielsen syndrome, a form of LQTS associated with deafness, a phenotypic abnormality inherited in an autosomal recessive fashion. Mutational analyses were used to screen 262 unrelated individuals with LQTS for mutations in the five defined genes. A total of 134 mutations were observed of which eighty were novel.Type: GrantFiled: August 9, 2000Date of Patent: January 29, 2002Assignee: University of Utah Research FoundationInventors: Igor Splawski, Mark T. Keating
-
Patent number: 6323026Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.Type: GrantFiled: November 22, 1999Date of Patent: November 27, 2001Assignee: University of Utah Research FoundationInventors: Mark T. Keating, Michael C. Sanguinetti, Igor Splawski
-
Patent number: 6277978Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes are also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.Type: GrantFiled: August 17, 1998Date of Patent: August 21, 2001Assignees: University of Utah Research Foundation, Genzyme CorporationInventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
-
Patent number: 6274332Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.Type: GrantFiled: August 17, 1998Date of Patent: August 14, 2001Assignee: Univ. of Utah Research FoundationInventors: Mark T. Keating, Michael C. Sanguinetti, Igor Splawski
-
Patent number: 6207383Abstract: The invention relates to the determination of the genomic structure of HERG which is a gene associated with long QT syndrome. The sequences of the 15 intron/exon junctions has been determined and this information is useful in devising primers for amplifying and sequencing across all of the exons of the gene. This is useful for determining the presence or absence of mutations which are known to cause long QT syndrome. Also disclosed are many new mutations in HERG which have been found to be associated with long QT syndrome.Type: GrantFiled: January 6, 1999Date of Patent: March 27, 2001Assignee: University of Utah Research FoundationInventors: Mark T. Keating, Igor Splawski
-
Patent number: 6150104Abstract: Jervell and Lange-Nielsen syndrome (JLN) is an autosomal recessive form of long QT syndrome. In addition to QT interval prolongation, this disorder is associated with congenital deafness. JLN is rare, but affected individuals are susceptible to cardiac arrhythmias with a high incidence of sudden death and short life expectancy. A homozygous mutation in KVLQT1, the potassium channel gene responsible for chromosome 11-linked long QT syndrome, is shown to be a cause of JLN.Type: GrantFiled: August 17, 1998Date of Patent: November 21, 2000Assignee: University of Utah Research FoundationInventors: Igor Splawski, Mark T. Keating
-
Patent number: 6063576Abstract: Two mutations in the human cardiac actin gene are disclosed which have been associated with idiopathic dilated cardiomyopathy (IDC) in two families. These mutations cosegregate with IDC in the two families. Both mutations affect universally conserved amino acids in domains of actin that attach to Z bands and intercalated discs. Analysis of the cardiac actin gene can be used to determine the presence in a patient of IDC resulting from mutations in this gene. Such analysis is useful in the diagnosis and prognosis of the disease in patients with mutations in this gene.Type: GrantFiled: June 29, 1998Date of Patent: May 16, 2000Assignee: University of Utah Research FoundationInventors: Mark T. Keating, Thomas M. Olson
-
Patent number: 5858662Abstract: Williams syndrome (WS) is a developmental disorder that includes poor visuospatial constructive cognition. This syndrome has been studied to identify genes important for human cognitive development. Two families are described which have a partial WS phenotype; affected members have the specific WS cognitive profile and vascular disease, but lack other WS features. Submicroscopic chromosome 7q11.23 deletions cosegregate with this phenotype in both families. DNA sequence analyses of the region affected by the smallest (83.6 kb) deletion revealed two genes, elastin (ELN) and LIM-kinasel (LIMK1). The latter encodes a novel protein kinase with LIM domains and is strongly expressed in the brain. Because ELN mutations cause vascular disease but not cognitive abnormalities, these data implicate LIMK1 hemizygosity in impaired visuospatial constructive cognition.Type: GrantFiled: July 10, 1996Date of Patent: January 12, 1999Assignees: University of Utah Research Foundation, University and College System of NevadaInventors: Mark T. Keating, Colleen A. Morris
-
Patent number: 5840489Abstract: The invention relates to the identification of the molecular basis of supravalvular aortic stenosis (SVAS) and Williams syndrome. More specifically, the invention has identified that elastin causes or is involved in the pathogenesis of SVAS and Williams syndrome. Molecular variants of the elastin gene contribute to SVAS and Williams syndrome. The analysis of the elastin gene will provide an early diagnosis of subjects with SVAS and Williams syndrome. The diagnostic method comprises analyzing the DNA sequence of the elastin gene of an individual to be tested and comparing it with the DNA sequence of the native, non-variant elastin gene. In a second embodiment, the elastin gene of an individual to be tested is screened for mutations associated with SVAS or Williams syndrome. Presymptomatic diagnosis of SVAS and Williams syndrome will enable practitioners to prevent vascular obstruction using existing medical therapies like beta adrenergic blocking agents.Type: GrantFiled: June 7, 1995Date of Patent: November 24, 1998Assignee: University of Utah Research FoundationInventors: Mark T. Keating, Mark F. Leppert, Colleen A. Morris
-
Patent number: 5650282Abstract: The invention relates to the identification of the molecular basis of supravalvular aortic stenosis (SVAS) and Williams syndrome. More specifically, the invention has identified that elastin causes or is involved in the pathogenesis of SVAS and Williams syndrome. Molecular variants of the elastin gene contribute to SVAS and Williams syndrome. The analysis of the elastin gene will provide an early diagnosis of subjects with SVAS and Williams syndrome. The diagnostic method comprises analyzing the DNA sequence of the elastin gene of an individual to be tested and comparing it with the DNA sequence of the native, non-variant elastin gene. In a second embodiment, the elastin gene of an individual to be tested is screened for mutations associated with SVAS or Williams syndrome. Presymptomatic diagnosis of SVAS and Williams syndrome will enable practitioners to prevent vascular obstruction using existing medical therapies like beta adrenergic blocking agents.Type: GrantFiled: June 7, 1995Date of Patent: July 22, 1997Assignee: The University of Utah Research FoundationInventors: Mark T. Keating, Mark F. Leppert, Colleen A. Morris
-
Patent number: 5599673Abstract: The invention relates to the identification of the molecular basis of long QT syndrome. More specifically, the invention has identified that SCN5A and HERG cause long QT syndrome. Molecular variants of the SCN5A and HERG genes contribute to the syndrome. The analysis of these genes will provide an early diagnosis of subjects with long QT syndrome. The diagnostic methods comprise analyzing the nucleic acid sequences of the SCN5A or HERG genes of an individual to be tested and comparing them with the nucleic acid sequence of the native, nonvariant genes. Alternatively, the amino acid sequences of SCN5A or HERG may be analyzed for mutations which cause long QT syndrome. Presymptomatic diagnosis of long QT syndrome will enable practitioners to treat this disorder using existing medical therapy.Type: GrantFiled: March 9, 1995Date of Patent: February 4, 1997Assignee: University of Utah Research FoundationInventors: Mark T. Keating, Mark E. Curran, Qing Wang